- Telo Genomics (TSXV:TELO) has revealed that the College of American Pathologists has accepted the company’s submission of its test for smoldering multiple myeloma, a rare blood cancer
- The company’s test, TeloViewSMM, has been accepted as a laboratory-developed test on Telo’s-CAP-approved menu of clinical tests
- TeloViewSMM addresses an unmet medical need in managing SMM patients
- Shares of Telo Genomics are up 13.16 per cent to C$0.215 as of 11:35 am ET
Telo Genomics (TSXV:TELO) has revealed that the College of American Pathologists (CAP) has accepted the company’s submission of its test for smoldering multiple myeloma (SMM), a rare blood cancer.
In a news release, the company stated its TeloViewSMM has been accepted as a laboratory-developed test on Telo’s CAP-approved menu of clinical tests.
The TeloViewSMM system is able to address unmet medical needs in managing SMM patients and can identify SMM patients with the highest risk of progression to full-stage multiple myeloma disease.
“Adding the TeloViewSMM to Telo’s CAP-approved tests menu is the official inauguration of this critical prognostic solution for smoldering myeloma patients as a clinical test,” Sherif Louis, president and CTO of Telo Genomics, said in a statement. “We look forward to enriching the management of myeloma disease with our MRD tests to monitor post-treated patients and accurately identify those with the highest risk of relapse prior to the relapse event.”
The TeloViewSMM test as a clinical test was validated in collaboration with the Mayo Clinic and the Dana Farber Cancer Institute and demonstrated superior sensitivity of 83 per cent, which is the accuracy in identifying high-risk patients, and specificity of 76 per cent, which is the accuracy in identifying stable patients.
CAP is an organization that serves patients, pathologists and the public by promoting the practice of pathology and laboratory medicine all around the world.
Telo Genomics is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Shares of Telo Genomics (TSXV:TELO) are up 13.16 per cent to C$0.215 as of 11:35 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Telo Genomics Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.